Learn More About PVSRIPO—A Unique, Potentially Transformative Viral Immunotherapy for Cancer

PVSRIPO, an investigational immunotherapy based on the live attenuated Sabin type 1 poliovirus vaccine, generates strong, durable, polyfunctional tumor antigen-specific T cell responses—the critical component for antitumor immunity. PVSRIPO has advanced into phase 2 trials in patients with recurrent glioblastoma, advanced melanoma, and a basket trial of solid tumors including muscle-invasive bladder cancer (MIBC).

PVSRIPO’s Unique Mechanism of Action Generates the Polyfunctional T Cells Required for Antitumor Immunity

  • Preclinical studies provide evidence that PVSRIPO’s nonlethal infection of antigen presenting cells (APCs) stimulates a key innate immune pathway, resulting in a sustained, robust type-I/III interferon-dominant inflammatory response1
    • Minimal release of unwanted cytokines associated with severe cytokine release syndrome
  • Clinical responses were observed in both injected and noninjected lesions during the phase 1 trial in advanced PD-1/L1–refractory melanoma2
    • This suggests a systemic antitumor immune response, which is being evaluated in the ongoing LUMINOS-102 phase 2 trial
  • Because polio vaccination is nearly universal and leads to strong, lifelong immunity, administration of PVSRIPO triggers an immune memory response that may augment PVSRIPO’s activity
  1. Brown MC, et al. Nature Commun. 2021;12:1858.
  2. Beasley GM, et al. J Immunother Cancer. 2021;9:e002203. doi:10.1136/jitc-2020-002203

Istari Oncology Research Pipeline: Unique Intratumoral Immunotherapy

Expanding potentially transformative therapy options for the treatment of a variety of solid tumors


Choose a topic that would better help us get in contact with you

Refer patients to one or more clinical trials

    Engage with or get updates from Istari Oncology

      Interested in being a clinical trial site?